Q-omics provides the consensus-scored ZNF235 profile across patient tissues and cancer cell-line models. ZNF235 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF235 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF235 RNA expression shows 21,925 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where ZNF235 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF235 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF235 survival associations across molecular data types. ZNF235 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF235 RNA expression–survival associations across cancer types. High ZNF235 expression shows unfavorable associations in LGG, LUSC and LIHC, but favorable associations in HNSC, KIRC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF235 RNA expression.
This table summarizes ZNF235 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF235. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF235 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, BLCA and CHOL. The THCA box plot shows higher ZNF235 RNA expression in normal versus tumor tissue (log2 FC = −0.887, t-test p < 0.001).
This table shows molecular features associated with ZNF235 in patient tissues and cancer cell lines. In patient samples, ZNF235 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF235 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
